Dr. Belldegrun has largely delivered on promises to raise money, assemble an experienced staff, build the factory, conduct clinical trials and begin to apply for regulatory approval. Once considered the underdog to Novartis and Juno, Kite might be the first reach the market. Academic centers and companies often drive harder bargains in licensing technology. In some cases, academic centers own a stake in a company they license technology to, allowing them to reap a financial windfall if the company does well. 